As the weekend approaches, film enthusiasts eagerly await the release of “Smile 2,” the highly-anticipated sequel from Paramount Pictures. Building on the remarkable success of its predecessor, which thrived in the theater landscape post-COVID, this sequel aims to capture the same magic that resonated with audiences in 2022. Initial presales hint at an opening weekend in the high teens, with earlier estimates suggesting it might exceed the $20 million mark—potentially hinging on the film’s reception, particularly among Latino and Hispanic audiences.
The first installment of “Smile” has become a notable case study in modern Hollywood, demonstrating how strategic marketing and distribution can lead to extraordinary box office performances. With its initial release grossing $22.6 million and eventually accumulating over $105 million domestically, the film defied expectations by pivoting from a potential streaming release to a successful theatrical rollout. This was a rarity during a time when many studios, like Disney, opted for home viewing platforms despite promising test screenings. “Hocus Pocus 2,” for instance, fell short of the theatrical experience, remaining exclusive to Disney+.
Now, with the original’s director Parker Finn back at the helm, “Smile 2” takes a fresh narrative direction. This sequel introduces Naomi Scott, known for her performances in “Power Rangers” and “Aladdin,” portraying a pop star grappling with the psychological turmoil brought on by her fame. As she contends with increasingly terrifying events linked to her past, the film beckons to explore themes of trauma, mental health, and the duality of fame.
The first “Smile” received a respectable critical reception, boasting an 80% rating on Rotten Tomatoes, while “Smile 2” has already achieved an 86% approval rating based on early reviews. This positive reception could indicate strong word-of-mouth and potential box office success, though one must consider the different market landscape this time around. Whereas the original released during a sparse horror film season following pandemic delays, “Smile 2” enters a market with more competition.
In contrast to its predecessor, which was the sole horror film prominently advertised, “Smile 2” faces the challenge of standing out among various genres vying for viewers’ attention, including films like the unrated “Terrifier 3.” This could affect its box office performance, particularly since “Terrifier 3” has already demonstrated impressive sales figures.
With a wide release across 3,500 theaters, “Smile 2” will utilize premium large formats (PLFs), though it notably lacks IMAX screenings due to contractual commitments to another film. The viewing demographics present another area of interest—with the R-rated sequel skewing predominantly toward a younger female audience, while competing films attract a more male-oriented viewer base.
The expectations surrounding “Smile 2” are nothing short of monumental. The film comes at a pivotal time for the horror genre in theaters, and its performance could provide invaluable insight into audience preferences and trends in post-pandemic cinema.
Leave a Reply